Response to androgen receptor signaling inhibitors (ARSI) varies widely in metastatic
castration resistant prostate cancer (mCRPC). To improve treatment guidance, biomarkers …

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53
profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer …

Background Biomarkers predicting second-generation novel hormonal therapy (NHT)
benefit relative to taxanes are critical for optimized treatment decisions for metastatic …

Abstract Background Metastatic prostate cancer (CaP) treatments are evolving rapidly but
without evidence-based biomarkers to predict responses, and to maximize remissions and …

Background Men with metastatic prostate cancer who are treated with androgen deprivation
therapy (ADT) typically develop therapeutic resistance eventually and have a dismal …

Background Genomic aberrations have been identified in metastatic castration-resistant
prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone …

Background Multiple therapies exist for patients with metastatic castration-resistant prostate
cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains …

Background Genomic alterations to the androgen receptor (AR) are common in metastatic
castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand …

Background Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the
disease. Several recent studies have identified genomic alterations in mCRPC, but the …